If you're living with retinitis pigmentosa, you've probably spent hours searching for anything that might slow the progression. One compound that's come up in those searches is 9-cis-beta-carotene—especially since a 2013 trial made some waves in the RP community. But what did that study actually find? And where does the research stand more than a decade later?
RP affects roughly 1 in 3,500 people in developed countries, making it the most common inherited cause of blindness. It typically starts with night blindness and shrinking peripheral vision, eventually progressing to tunnel vision and sometimes total blindness. That gradual but relentless course drives the urgent hunt for therapies that can preserve what vision remains.
The 2013 trial in JAMA Ophthalmology was genuinely notable—it gave us the first controlled human data on 9-cis-β-carotene for RP. Here's what we know, what we don't, and what it means for patients trying to make sense of their options.
Symptoms
9-cis-beta-carotene retinitis pigmentosa presents with the classic RP symptom pattern. Patients typically experience night blindness first, as rod photoreceptors deteriorate. Peripheral vision gradually constricts, creating "tunnel vision." Many develop photophobia and difficulty with dark adaptation. Color vision often fades later, and central vision may eventually decline. The 2013 trial specifically tested whether 9-cis-beta-carotene could improve dark-adapted visual function—measuring exactly the symptoms that trouble patients most.
Causes
The underlying causes of 9-cis-beta-carotene retinitis pigmentosa involve the same genetic mutations driving other RP forms. Mutations in RPE65, LRAT, RDH5, and similar genes disrupt the retinoid cycle—the chemical relay regenerating 11-cis-retinal. When this cycle stalls, photoreceptors starve for functional pigment and accumulate toxic byproducts. The rationale for 9-cis-beta-carotene specifically targets these retinoid cycle defects, offering an alternate biochemical route to produce usable visual pigment.
Diagnosis
Diagnosing 9-cis-beta-carotene retinitis pigmentosa candidates requires comprehensive inherited retinal disease workup. Genetic testing identifies retinoid cycle mutations most likely to respond. Electroretinography quantifies photoreceptor function. Optical coherence tomography reveals retinal structure. Dark adaptometry measures the specific impairment this compound might address. The 2013 trial used these objective measures to select and monitor participants—essential for any consideration of this experimental approach.
Treatment
Treatment with 9-cis-beta-carotene for retinitis pigmentosa remains investigational. The 2013 trial used 60 mg daily of algal-derived powder for 90-day periods. Results showed statistically significant improvements in dark-adapted visual field area during treatment, with reversal when stopped. However, no pharmaceutical product exists. Gene therapy with voretigene neparvovec now offers established treatment for biallelic RPE65 disease. For other genotypes, 9-cis-beta-carotene represents one of few pharmacological approaches with any controlled human data, though availability remains limited to research settings.
Why This Compound? The Science Behind Visual Cycle Support
RP isn't one disease—it's dozens, caused by mutations in more than 80 different genes. But many forms share a common problem: the retinoid cycle breaks down. This is the chemical relay between your photoreceptors and the retinal pigment epithelium that regenerates 11-cis-retinal, the molecule that actually lets you see. When that cycle stalls, photoreceptors starve for functional pigment and get poisoned by toxic buildup.
Back in 2018, Sher and colleagues showed something promising in rpe65rd12 mice. In eye cup cultures, synthetic 9-cis-beta-carotene actually slowed photoreceptor death. The idea is elegant: the compound skips past the broken enzymatic steps, offering an alternate route to make the chromophore you need.
That mechanism made researchers hopeful for human trials—particularly for people whose RP stems from retinoid cycle defects. But promising biology doesn't always translate. The 2013 trial let us test that leap.
The 2013 Trial: What Actually Happened
Rotenstreich's team enrolled 29 RP patients with various genetic backgrounds. Each person spent 90 days taking 60 mg daily of 9-cis-β-carotene powder (extracted from Dunaliella bardawil algae), then 90 days off, then 90 days on placebo—or the reverse order. This crossover design meant every patient served as their own control, which helped account for the huge genetic variability in RP.
They measured what you'd expect: dark-adapted visual fields, ERG responses, visual acuity, and contrast sensitivity. They also tracked serum retinoid levels and safety.
The headline: treated periods showed statistically significant improvements in dark-adapted visual field area compared to placebo. ERG changes were modest and not universal. Visual acuity and contrast sensitivity didn't really budge.
Here's the part that matters for interpretation: when patients stopped treatment, their vision slid back toward baseline. When they restarted, it improved again. That reversibility is scientifically interesting—it confirms the compound was doing something—but it also frames what we're looking at. This isn't a treatment that fixes underlying damage. It's closer to a functional boost that lasts while you're taking it.
And the benefits weren't equal. People with earlier-stage disease responded more strongly. Once photoreceptors are largely gone, apparently, this approach can't bring them back.
The Caveats: Reading This Study Critically
The 2013 results got attention for good reason, but several limitations deserve honest discussion.
Small numbers, short times. Twenty-nine people across many genetic subtypes doesn't give you power to detect who benefits most. And 90 days, while enough to see biological activity, tells you nothing about whether this helps over the years and decades that RP unfolds.
Genetic mixing bowl. The trial included whatever RP mutations walked through the door—rhodopsin, Usher syndrome, retinoid cycle defects, and others. The mechanistic rationale specifically fits RPE65, LRAT, and similar mutations. For other forms, the theoretical basis is shakier. We simply don't know from this study who responds best.
What kind of improvement? Larger visual fields in dark conditions are genuinely useful. But temporary functional enhancement isn't the same as slowing disease progression. Without longitudinal imaging data—OCT thickness, autofluorescence patterns—we can't say whether photoreceptors were being preserved or just working harder while dosed.
Crossover complications. These designs assume washout periods clear the drug completely. With 90 days off, that may not have happened. If retinal effects lag behind blood levels, you could see "placebo" responses that are really residual treatment effects, or true effects that look smaller than they are. It's a methodological trade-off without a clean answer.
The Lab Work That Supports (But Doesn't Prove) the Concept
The clinical trial didn't emerge from nowhere. Two preclinical studies helped build the case.
In 2014, Ozaki's group treated Rpe65 knockout mouse retinas with algal 9-cis-β-carotene. The compound protected cone opsins and improved survival—direct evidence that the unprocessed molecule reaches target tissue and does something useful. The algal source mattered: Dunaliella bardawil naturally enriches this isomer under stress, which is why the clinical trial used it.
Sher's 2018 work went further, using chemically pure synthetic 9-cis-beta-carotene in the same model. They showed dose-dependent protection and measurable 9-cis-retinal production. Together, these studies outline a coherent story: the compound gets converted to 9-cis-retinal, which forms "isorhodopsin"—a slightly blue-shifted but functional visual pigment that can stand in for the missing 11-cis version.
That's solid mechanistic grounding. It just doesn't guarantee clinical success.
Why You Can't Get It (Despite the Published Data)
More than ten years after that trial, 9-cis-β-carotene remains unavailable as a standard treatment. Here's why.
No drug product exists. The algal powder used in 2013 wasn't manufactured to pharmaceutical standards. Algal supplements with mixed carotenoids are sold as wellness products, but their 9-cis-β-carotene content varies wildly. Synthetic 9-cis-beta-carotene is still experimental. There's no reliable way to replicate the 60 mg dose outside a research setting.
Regulatory precedent didn't help. Rotenstreich's team had already shown similar functional improvements in fundus albipunctatus patients in 2010—another retinoid cycle disorder. That didn't lead to approval either. Published evidence and regulatory authorization are different worlds.
The landscape shifted. When voretigene neparvovec (Luxturna) won FDA approval in 2017 for biallelic RPE65 mutations, it became the standard for that specific genotype. Gene therapy offers something 9-cis-β-carotene doesn't: sustained benefit from a single treatment, actually addressing the genetic defect. That success left oral visual cycle modulators in an awkward position—still potentially relevant for the majority of RP patients without RPE65 mutations, but harder to develop commercially.
If You're Considering This: Practical Realities
For patients and families researching options, a few grounded points:
Research isn't recommendation. The 2013 trial had inclusion criteria, monitoring protocols, and defined endpoints. Taking algal supplements based on internet reading isn't the same thing—and isn't medically advised without specialist involvement.
Product quality is a genuine problem. Even "high-quality" Dunaliella supplements don't standardize for 9-cis-β-carotene content. Growth conditions, strain selection, and processing all affect isomer ratios. You can't know what you're getting.
Interactions with vitamin A matter. Many RP patients already take vitamin A palmitate based on older trial data. How retinol and 9-cis-β-carotene metabolism interact isn't well characterized. Combining them might do unexpected things to your serum retinoid profile.
Monitoring isn't optional. The trial used regular exams, electrophysiology, and visual fields. Any experimental approach needs equivalent objective tracking—not just "I feel like I see better."
Where This Fits Among Your Options
| Approach | How it works | Evidence strength | Availability |
|---|---|---|---|
| Vitamin A palmitate | Antioxidant, supports retinoid metabolism | Multiple RCTs | Standard recommendation |
| 9-cis-β-carotene | Bypasses blocked visual cycle steps | One RCT, supportive lab work | Research only |
| RPE65 gene therapy | Corrects the genetic defect directly | Phase III, FDA approved | For confirmed biallelic RPE65 disease |
| Ciliary neurotrophic factor | Tries to protect neurons | Failed in Phase III | Not available |
| Retinal prostheses | Replaces photoreceptor function with electronics | Approved devices | For end-stage vision loss |
For the majority of RP patients—those without RPE65 mutations—9-cis-β-carotene represents one of the few pharmacological approaches with any controlled human data. That partly explains why interest persists despite its limitations.
What We'd Need to Know More
Several genuine research gaps remain:
Genotype-specific trials. Restricting to RPE65, LRAT, or RDH5 mutations could clarify whether benefits cluster where theory predicts. The fundus albipunctatus results hint this might be true.
Structural outcomes. Long-term OCT and autofluorescence could separate functional enhancement from true neuroprotection—essential for understanding whether you're changing the disease course or just borrowing better vision temporarily.
Combination possibilities. For RPE65 disease, might this help during the lag before gene therapy takes full effect? No one has tested this.
Better delivery. Transdermal, sublingual, or sustained-release formulations might improve absorption. We still don't fully understand how 9-cis-β-carotene moves through human bodies.
FAQ
What's the difference between 9-cis-beta-carotene and regular beta-carotene?
Same atoms, different shape—specifically at the 9-carbon position. Standard dietary beta-carotene is mostly "all-trans," which needs several enzymatic steps to become visual pigment. The 9-cis form can convert directly to 9-cis-retinal, shortcutting past broken steps in certain RP forms. It's a detour around roadblocks in the retinoid cycle.
Does 9-cis-beta-carotene cure retinitis pigmentosa?
No. The 2013 trial showed reversible improvements in some visual functions during treatment. That's not cure, not halted progression, not reversed damage. It's temporary functional enhancement for some patients.
Can I buy 9-cis-beta-carotene for retinitis pigmentosa?
Not reliably. Pharmaceutical-grade 9-cis-β-carotene doesn't exist as an RP treatment. Algal supplements vary enormously in content. Self-supplementation based on research reading isn't medically recommended.
Which genetic types of retinitis pigmentosa might respond to 9-cis-beta-carotene?
The mechanism points to retinoid cycle defects—RPE65, LRAT, RDH5. The fundus albipunctatus study and mouse models support this. But the 2013 RP trial mixed genotypes without reporting separately, so we don't actually know. Rhodopsin mutations and other non-cycle mechanisms probably benefit less, if at all.
How does 9-cis-beta-carotene compare to Luxturna for retinitis pigmentosa?
Gene therapy for RPE65 provides durable, meaningful improvement by fixing the underlying genetic problem. 9-cis-β-carotene offers temporary, reversible functional enhancement without touching the genetic defect. For eligible patients, gene therapy is the established choice; this compound remains experimental for everyone.
What side effects occurred with 9-cis-beta-carotene in retinitis pigmentosa trials?
Yellow skin from carotenoid accumulation—expected and harmless. No serious problems emerged, though 29 people over 90 days can't rule out rare or long-term issues.
Is research on 9-cis-beta-carotene for retinitis pigmentosa continuing?
Specific clinical programs for 9-cis-β-carotene in RP appear limited. It hasn't advanced to Phase III. Broader visual cycle research continues, but this particular compound seems stalled. Check clinical trial registries if you're interested in participation.
The Bottom Line
The evidence for 9-cis-beta-carotene in retinitis pigmentosa rests on one modest randomized trial showing temporary, reversible visual field improvements, backed by coherent laboratory studies of how it might work. That's genuinely more than many RP interventions can claim. But it's not enough to make this a standard treatment.
The 2013 study's real contribution may be broader: it proved that targeting the visual cycle can produce measurable benefits in human RP, helping validate an approach that later produced approved gene therapy for specific mutations. Whether 9-cis-β-carotene itself will advance further is uncertain.
If you're exploring this, talk with a retina specialist who knows inherited diseases. Consider formal research participation.
FDA Medical Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Educational Purpose Only: The research and biomedical studies provided on this page are for informational and educational purposes only. They are intended to explain the mechanism of the 9-cis molecule. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.